BIO-FAct Sheet May31-2016

Transporting Therapeutics into the Brain
FACT SHEET
OTCQB: BIOAF
TSX.V: BTI
Q2 - 2016
MARKET PROFILE
biOasis Technologies Inc. is a biopharmaceutical company that has discovered a
breakthrough carrier technology that addresses one of the largest unmet medical
needs in neurological medicine today. This patented carrier uses a naturally
SHARES 0/S
45,379,257
occurring biological process to transport drugs into the brain for the treatment of over a thousand common and rare diseases of the brain and the central
nervous system.
FULLY DILUTED
CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
The delivery of therapeutics across the blood brain barrier (“BBB”) has been
52,874,257.
considered the holy grail of neurological science for decades. As a result,
treatments for over 1,000 different CNS disorders remain ineffective.
MARKET CAP
> $61 MILLION
(May 12, 2016)
OWNERSHIP
INSIDERS & AFFILIATES ~35%
INSTITUTIONAL ~10%
www.bioasis.ca/market-profile/
CNS DISORDERS AFFECT 1 IN 6 PEOPLE. ALL TREATMENTS ARE HINDERED BY THE BLOOD BRAIN BARRIER.
The Problem
THE BLOOD BRAIN BARRIER
The BBB is a network of capillaries that
deliver oxygen and other necessities to
brain cells, but the walls of the
capillaries have a layer of endothelial
cells that are tightly joined together so
foreign substances cannot pass from the blood into the brain tissue. Unfortunately they also reject beneficial
therapeutics from entering the brain.
The BBB BlocksTherapeutics
• 98% of small molecule drugs
• 100% larger molecule drugs
biOasis has discovered a breakthrough solution…
OUR SOLUTION
biOasis has discovered a natural, biological process, that when
linked to pre-existing therapeutics, can transport these
medicines across the BBB and into the brain tissue, which offers
the potential to address one of the largest unmet medical needs
in neurological medicine today.
Brain Tissue
THE TRANSCEND PLATFORM
biOasis’ Transcend Platform is a group of proprietary
technologies designed for the transport of therapeutic agents
across the BBB by linking pre-existing & new therapeutics to
MTf & MTfpep, which freely cross the BBB through receptors
A tightly woven capillary network of endothelial cells
lines the blood vessels, blocking toxic compounds
from entering the brain tissue.
located on the brain capillary wall to deliver drugs across the
BBB and into the brain tissue.
Original Discovery: MTf
•
A natural human protein known as Melanotransferrin (MTf
or p97) found at low concentrations in the blood which
exists in all mammals on planet earth
New Discovery: MTfpep
•
A newly discovered peptide derived from the full-length MTf
protein that facilitates transport of MTf across the BBB
•
•
A fragment of the original MTf protein
Offers greater commercialization potential vs. MTf alone
ADVANTAGES OF THE NEW DISCOVERY
• Higher commercial value over MTf
• Greater efficiency of BBB delivery
• Lower cost of production
• Improved quality control
• Simpler to link to therapeutics
• Transports a variety of compounds
• Extends biOasis patent portfolio
• Pharmaceutical collaborator licensing,
Transcendpep
validating the technology
The delivery of therapeutics across the BBB represents the single greatest challenge in the
treatment of over a thousand common and rare diseases of the brain and central nervous system
MANAGEMENT
Board Of Directors
Team
Rob Hutchison, Chair & CEO
Former: CEO of eCharge Corporation
Reinhard Gabathuler, PhD Chief Scientist
Former: VP Brain Research, Biomarin
Chris Fibiger, PhD
Former: Head of Neuroscience, Amgen & Eli Lily
Mei Mei Tian, PhD, Scientist
Expertise in MTf & BBB transport
Greg Gubitz, LLB
Former: VP, Biovail Corporation & COO, MDS
Capital
Judi Dalling, LLB, CFO
Seasoned public company CFO and lawyer
Terry Pearson, PhD
Professor: Biochemistry & Microbiology, UVIC
Discovered & commercialized SISCAPA Assay
Kim Elton, Director Marketing & Communications
Shadow Lake Group Business Development Consultants
Ron Erickson
Chair & CEO, Visulant Technologies
Michael Hutchison, QC, LLB
Partner, Smith Hutchison Law Corporation
Market Opportunity
Collaborations
Patent Cliff Licensing Agreements
Offers potential patent extensions to the
pharmaceutical industry through New Chemical
Entity designation for many preexisting, patentexpiring drugs.
Astellas Research Institute of America LLC
Unmet Medical Need
Assists in development of new therapies for
currently untreatable diseases and revitalizes
dormant candidates that could be efficacious if
delivered to the brain.
Research Agreement
Market Growth
Brains For Brain Foundation, Italy
Contributes to the growth in CNS drug market by
opening up a market that has been stagnated by
ineffective drug delivery to the brain.
To partner with us:
[email protected]
604-644-1232
R&D HIGHLIGHTS
Full-Length: MTf
Peptide: MTfp
Brain Cancer: Metastatic Breast Cancer
Herceptin® & MTf conjugate
40% of HER2+ breast cancer patients develop
metastatic brain cancer, which is largely untreatable
RESULTS
• 68% of HER2+ tumours were eliminated
•
•
siRNA: MTfp
siRNA (small Interfering RNA): potential to reverse & eradicate human disease by targeting specific
genes that modify disease outcome
RESULTS
• MTfpep was shown to effectively deliver siRNA
84% overall total tumour volume reduction
across the BBB, modifying gene expression Penetrated the blood-tumour barrier >20 times
by 40-50%
better than Herceptin® alone
Metabolic Lysosomal Storage Diseases: MPS l & MPS ll
• Lysosomal Enzymes & MTf Conjugate
• Rare inherited metabolic diseases caused by
enzyme deficiencies, currently untreatable in the
brain tissue
RESULTS
• Increased IDU brain enzyme activity ~6 fold for
•
MTfpep-siRNA was shown to reduce brain damage and improve overall brain activity in a stroke model
•
MTfpep-mAb showed therapeutic levels of
delivery to brain over a 14.5 day period. 68% of
HER2+ tumours were eliminated
PROGRAMS 2015-2016
MPS l and increased IDS brain enzyme activity
• Brain Cancer
• Metabolic Disease
• siRNA
~20 fold for MPS ll better than the enzyme I2S
Neurodegenerative Diseases:
Alzheimer’s Disease
Anti-Aβ Antibody & MTf conjugate
Antibodies directed at Aβ are potential therapeutics
for reducing amyloid plaques in the brain
RESULTS
• Increases transport into brain tissues by ~8 fold
Disclaimer
Certain statements in this Factsheet contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under
applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”,
“continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that
may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forwardlooking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the
completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the
prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or
results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and
information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted
corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no
experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology
companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking
statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by law.
biOasis Technologies Inc.
130 - 10691 Shellbridge Way, Richmond BC, Canada V6X 2W8
T: (604) 295-7014 E: [email protected] | www.bioasis.ca